Cardiac Allograft Vasculopathy Clinical Trial
— EVOLVDOfficial title:
EVOLVD: Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
Verified date | October 2023 |
Source | Oslo University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main goal of this study is to evaluate the effect of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab on cardiac allograft vasculopathy in de novo heart transplant recipients. Secondary objectives are to assess the impact of treatment on: i) cholesterol levels, ii) renal function, iii) inflammation, iv) quality of life, v) cardiac function as assessed by biomarkers and echocardiography, vi) the number of rejections, and (vii) safety and tolerability. As an exploratory outcome, the investigators will asses the effect of treatment on clinical events (death, myocardial infarction, cerebral stroke, cancer, end stage renal disease).
Status | Completed |
Enrollment | 130 |
Est. completion date | May 20, 2023 |
Est. primary completion date | May 20, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: Patients will be screened for eligibility during routine follow-up 4 - 8 weeks after heart transplantation. All of the following conditions must apply prior to administering the investigational medicinal product: - Heart transplant recipient within the last 4 - 8 weeks. - Age between 18 and 70 years. - Informed consent obtained and documented according to Good Clinical Practice (GCP), and national/regional regulations. - No contraindications to coronary angiography with intravascular ultrasound - Estimated glomerular filtration rate > 20 ml/min/1.73 m2 as assessed by the MDRD formula. Exclusion Criteria: Patients will be excluded from the study if they meet any of the following criteria: - Decompensated liver disease (Child-Pugh class C) - Severe renal failure, i.e. eGFR < 20 ml/min/1.73 m2 or on renal replacement therapy - Ongoing rejections or infections - Known sensitivity or intolerance to evolocumab or any of the excipients of Repatha® - Prior use of PCSK9 inhibition treatment - Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake - Participation in another clinical trial involving an investigational drug and/or follow-up within 30 days prior to enrolment. - Pregnancy. - Female subject who has either (1) not used at least one highly effective method of birth control for at least 1 month prior to screening or (2) is not willing to use such a method during treatment and for an additional 15 weeks after the end of treatment, unless the subject is sterilised or postmenopausal. |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Cardiology, Rigshospitalet | Copenhagen | |
Denmark | Department of Cardiology, Aarhus University Hospital | Skejby | |
Finland | Helsinki University Hospital Heart and Lung Center | Helsinki | |
Sweden | Department of Cardiology, Sahlgrenska University Hospital | Gothenburg | |
Sweden | The Clinic for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University | Lund |
Lead Sponsor | Collaborator |
---|---|
Lars Gullestad | Aarhus University Hospital, Helsinki University Central Hospital, Rigshospitalet, Denmark, Sahlgrenska University Hospital, Sweden, Skane University Hospital |
Denmark, Finland, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximal intimal thickness | The maximal intimal thickness will be measured by coronary intravascular ultrasound at 12 months after randomization. The maximal intima thickness is defined as the largest distance (in mm) from the intimal leading edge to the external elastic membrane. | 12 months | |
Secondary | Cardiac allograft vasculopathy | Incidence of cardiac allograft vasculopathy, defined as mean a maximal intimal thickness =0.5 mm over the entire matched segment, will be measured by intravascular ultrasound 12 months after randomization. | 12 months | |
Secondary | Total atheroma volume | The total atheroma volume will be measured by intravascular ultrasound. | 12 months | |
Secondary | The index of microvascular resistance | The index of microcirculatory resistance will be obtained at the time of routine coronary angiography after heart transplantation at baseline (4-10 weeks) and at the end of treatment 12 months after randomization. | 12 months | |
Secondary | Low-density lipoprotein (LDL) cholesterol | Blood lipids must be assessed after end-of treatment only, to avoid what will effectively amount to study drug allocation unblinding. To avoid bias, the investigators will be blinded to the lipid analyses. | 12 months | |
Secondary | Estimated glomerular filtration rate (eGFR) | The glomerular filtration rate (in in ml/min/1.73 m2) will be estimated by the MDRD formula: 175 x (SCr)-1.154 x (age)-0.203 x 0.742 [if female] x 1.212 [if black], where SCr is serum creatinine in mg/dl, and age is measured in years. | 12 months | |
Secondary | The 36-item short form health survey questionnaire (SF-36) | The SF-36 Health Survey is a 36-item, patient-reported survey of patient health. | 12 months | |
Secondary | The 3-level version of EQ-5D (EQ-5D-3L) questionnaire | The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. | 12 months | |
Secondary | The Beck Depression Inventory (BDI) | The BDI is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. | 12 months | |
Secondary | N-terminal pro-B-type natriuretic peptide (NT-proBNP) | NT-proBNP values will be used for endpoint analyses. | 12 months | |
Secondary | Cardiac troponin T (TnT) | Troponin T-values will be used for endpoint analyses. | 12 months | |
Secondary | Number of rejections | Number of all rejections will be recorded through the duration of the study. | 12 months | |
Secondary | Number of adverse events (AE) | The standard time period for collecting and recording AE and SAEs will begin at the start of study treatment and will continue for 30 day after end-of treatment (at which time approximately 30 days will have passed since the last study drug injection. | 12 months | |
Secondary | Number of major clinical adverse events | The number of major clinical adverse events, defined as death, myocardial infarction, percutaneous coronary intervention/coronary bypass surgery, cerebral stroke, cancer, end stage renal disease (exploratory endpoint). | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02880137 -
Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy
|
Phase 4 | |
Terminated |
NCT01848301 -
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
|
Phase 1 | |
Terminated |
NCT01278745 -
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
|
Phase 2 | |
Withdrawn |
NCT01812434 -
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
|
N/A | |
Withdrawn |
NCT01305382 -
Noninvasive Evaluation of Cardiac Allograft Vasculopathy
|
N/A | |
Recruiting |
NCT05826444 -
Microvascular Cardiac Allograft Vasculopathy Trial
|
||
Suspended |
NCT05756088 -
Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
|
||
Completed |
NCT02013037 -
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
|
Phase 3 | |
Withdrawn |
NCT01157949 -
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
|
Phase 3 | |
Withdrawn |
NCT01305395 -
Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
|
N/A | |
Enrolling by invitation |
NCT06147271 -
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT04193306 -
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT02798731 -
Physiologic Assessment of Microvascular Function in Heart Transplant Patients
|
||
Withdrawn |
NCT02777255 -
Severe CAV MRI in Heart Transplant Recipient
|
N/A | |
Completed |
NCT05373108 -
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
|
Phase 4 | |
Withdrawn |
NCT01424917 -
Noninvasive Predictors of Transplant Vasculopathy
|
N/A | |
Recruiting |
NCT04770012 -
AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT01078363 -
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
|
N/A | |
Recruiting |
NCT06089486 -
MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation
|
N/A | |
Active, not recruiting |
NCT03386539 -
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
|
Phase 3 |